Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanism and preclinical in vivo studies with no new human clinical data
PubMed 29514064 · doi:10.1016/j.cmet.2018.02.011
What was done
This narrative review summarizes in vivo evidence regarding nicotinamide adenine dinucleotide (NAD+) biology, its age-related decline, and the preclinical effects of NAD-boosting molecules on health and lifespan in animal models.
What was found
The abstract contains no quantitative metrics or numerical data. It qualitatively reports that NAD+ levels decline with age, altering metabolism and raising disease susceptibility, while restoring NAD+ in aged or diseased animals promotes health and extends lifespan.
Why it matters
It highlights NAD+ replenishment as a systemic therapeutic strategy aimed at increasing physiological resilience against multiple aging-related diseases.
Limits
The review relies primarily on preclinical animal evidence with no human clinical trial data reported in the abstract. Quantitative effect sizes, study counts, and systematic search criteria are absent.
Cited by
- supports Nicotinamide adenine dinucleotide (NAD) is an essential cofactor utilized in approximately 450 cellular chemical reactions.